๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

27 recruiting trials

for Relapsed/Refractory Primary Central Nervous System Lymphoma

Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL NCT07074470NA1 site๐Ÿ“ Suzhou The First Affiliated Hospital of Soochow University ยท Tests: Induction therapy-2 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor), Consolidation therapy with ASCโ€ฆ Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma NCT05209620Phase 21 site๐Ÿ“ Zhengzhou Henan Cancer Hospital ยท Tests: ICP-022, Pemetrexed Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). NCT06213636Phase 1, Phase 21 site๐Ÿ“ Beijing Essen Biotech ยท Tests: CD19/CD22-CAR T cells CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) NCT03328078Phase 1, Phase 245 sites๐Ÿ“ Phoenix๐Ÿ“ Phoenix๐Ÿ“ Duarte Curis, Inc. ยท Tests: Emavusertib, Ibrutinib A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) NCT07082868Phase 18 sites๐Ÿ“ Basking Ridge๐Ÿ“ Middletown๐Ÿ“ Montvale Memorial Sloan Kettering Cancer Center ยท Tests: ibrutinib, Epcoritamab A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites๐Ÿ“ Duarte๐Ÿ“ Orange๐Ÿ“ San Francisco Nurix Therapeutics, Inc. ยท Tests: NX-2127 Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma NCT07062627Phase 21 site๐Ÿ“ Seoul Hyungwoo Cho ยท Tests: Anbal-cel A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NCT05131022Phase 162 sites๐Ÿ“ Duarte๐Ÿ“ San Francisco๐Ÿ“ Denver Nurix Therapeutics, Inc. ยท Tests: NX-5948 The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients. NCT05931328Phase 21 site๐Ÿ“ Nanjing The First Affiliated Hospital with Nanjing Medical Universiโ€ฆ ยท Tests: thiotepa combined with pomalidomide Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas NCT05681195Phase 21 site๐Ÿ“ Miami Baptist Health South Florida ยท Tests: Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT), Whole Brain Radiation Therapy (WBRT) NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL NCT06737250Phase 210 sites๐Ÿ“ Busan๐Ÿ“ Hwasun๐Ÿ“ Ilsan NOBO Medicine ยท Tests: R2P -> RP Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma NCT07416890Phase 21 site๐Ÿ“ Hangzhou Zhejiang Cancer Hospital ยท Tests: Thiotepa, Pirtobrutinib , Sintilimab(TPS) CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies NCT04186520Phase 1, Phase 21 site๐Ÿ“ Milwaukee Medical College of Wisconsin ยท Tests: 8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) NCT06343311Phase 1, Phase 25 sites๐Ÿ“ Sacramento๐Ÿ“ Cleveland๐Ÿ“ Portland Estrella Immunopharma, Inc. ยท Tests: EB103 Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma NCT04961515Phase 21 site๐Ÿ“ Hangzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Orelabrutinib, Sintilimab, Temozolomide (TMZ) Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab NCT06931652Phase 213 sites๐Ÿ“ Bordeaux๐Ÿ“ Caen๐Ÿ“ Clermont-Ferrand The Lymphoma Academic Research Organisation ยท Tests: Epcoritamab Phase Ib Clinical Study of Keynatinib NCT04807881Phase 14 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Shanghai Medolution Ltd. ยท Tests: Keynatinib Selinexor in Combination With MTX+Ritu to Treat R/R CNSL NCT05698147Phase 1, Phase 25 sites๐Ÿ“ Hefei๐Ÿ“ Beijing๐Ÿ“ Fuzhou Tong Chen, MD ยท Tests: Selinexor, Rituximab, Methotrexate Pembrolizumab, Ibrutinib and Rituximab in PCNSL NCT04421560Phase 1, Phase 24 sites๐Ÿ“ Boston๐Ÿ“ Boston๐Ÿ“ New York Dana-Farber Cancer Institute ยท Tests: Ibrutinib, Pembrolizumab, Rituximab Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU NCT06116110n/a11 sites๐Ÿ“ Gilbert๐Ÿ“ Stanford๐Ÿ“ New Haven Miltenyi Biomedicine GmbH ยท Tests: Long-term Follow-Up Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma NCT07523737Phase 21 site๐Ÿ“ Beijing Beijing Tongren Hospital ยท Tests: Pomalidomide, PD-1 / PD-L1 monoclonal antibody, XPO1 inhibitor A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma๏ผˆSELINA๏ผ‰ NCT07191431NA1 site๐Ÿ“ Shanghai Ruijin Hospital ยท Tests: Selinexor+Orelabrutinib+Methotrexate/Thiotepa/Temozolomide IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) NCT07104032Phase 338 sites๐Ÿ“ Phoenix๐Ÿ“ Scottsdale๐Ÿ“ Fullerton Ono Pharmaceutical Co., Ltd. ยท Tests: Tirabrutinib, Rituximab, Temozolomide A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma NCT06556199Phase 1, Phase 21 site๐Ÿ“ Hanzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Selinexor, Temozolomide, Anti-PD-1 monoclonal antibody CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma NCT04870944Phase 1, Phase 235 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Los Angeles Children's Oncology Group ยท Tests: Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Echocardiography Test, FACT Complex-targeting Curaxinโ€ฆ A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL) NCT07137494Phase 17 sites๐Ÿ“ Basking Ridge๐Ÿ“ Middletown๐Ÿ“ Montvale Memorial Sloan Kettering Cancer Center ยท Tests: MB-CART19.1 Cellular Therapy DALY II USA/ MB-CART2019.1 for DLBCL NCT04792489Phase 232 sites๐Ÿ“ Birmingham๐Ÿ“ Gilbert๐Ÿ“ Phoenix Miltenyi Biomedicine GmbH ยท Tests: zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy